Inclusion Criteria:

          -  Has a histologically-confirmed diagnosis of unresectable, locally advanced/metastatic
             RCC with clear cell component (with or without sarcomatoid features) (may include
             participants with a diagnosis of von Hippel-Lindau [VHL] associated ccRCC).

          -  Has experienced disease progression on or after having received at least one previous
             systemic treatment for advanced ccRCC.

          -  Shows adequate organ function.

          -  Male participants are eligible to participate if they are abstinent from heterosexual
             intercourse or agree to use contraception during the intervention period and for at
             least 7 days after the last dose of study intervention.

          -  A female participant is eligible to participate if she is not pregnant or
             breastfeeding, and is not a woman of childbearing potential (WOCBP) or is a WOCBP and
             using contraception or is abstinent from heterosexual intercourse during the
             intervention period and for at least 30 days after the last dose of study
             intervention.

        Exclusion Criteria:

          -  Has hypoxia, or requires intermittent supplemental oxygen, or requires chronic
             supplemental oxygen.

          -  Has a known additional malignancy that is progressing or has required active treatment
             within the past 3 years. Note: The time requirement does not apply to participants who
             underwent successful definitive resection of basal cell carcinoma of the skin,
             squamous cell carcinoma of the skin, superficial bladder cancer, in situ cervical
             cancer, or other in situ cancers.

          -  Has any history of or current brain or meningeal metastasis.

          -  Has clinically significant cardiac disease, including unstable angina, acute
             myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA), or
             coronary artery bypass graft surgery (CABG) ≤6 months from Day 1 of study drug
             administration, or New York Heart Association Class III or IV congestive heart
             failure. Medically controlled arrhythmia stable on medication is permitted.

          -  Has moderate to severe hepatic impairment.

          -  Has an active infection requiring therapy (includes tuberculosis).

          -  Has known human immunodeficiency virus (HIV) and/or hepatitis B or C infections or is
             known to be positive for hepatitis B surface antigen (HBsAg)/hepatitis B virus (HBV)
             deoxy ribonucleic acid (DNA) or hepatitis C antibody or ribonucleic acid (RNA).

          -  Has a history or current evidence of a gastrointestinal (GI) condition (eg,
             inflammatory bowel disease, Crohn's disease, ulcerative colitis) or impaired liver
             function.

          -  Has had major surgery ≤3 weeks prior to first dose of study intervention.

          -  Has received prior treatment with belzutifan.

          -  Has received any type of systemic anticancer antibody (including investigational
             antibody) ≤4 weeks prior to the first dose of study intervention.

          -  Has recovered from all AEs due to previous therapies to ≤ Grade 1 or baseline.
             Participants with a ≤ Grade 2 neuropathy may be eligible.

          -  Has received prior radiotherapy within 2 weeks prior to randomization.

          -  Has received colony-stimulating factors (CSFs) (e.g., granulocyte-CSF [G-CSF],
             granulocyte monocyte-CSF [GM-CSF] or recombinant erythropoietin [EPO]) ≤28 days prior
             to the first dose of study intervention.

          -  Has participated and received study intervention in a study of an investigational
             agent or has used an investigational device within 4 weeks prior to the first dose of
             study intervention. Note: Participants who have entered the follow-up phase of an
             investigational study may participate as long as it has been at least 4 weeks since
             the last dose of the previous investigational agent.